[Current Data] Rule running report - 2023-10-27 04:49:21.312954

Nr2MedPage Today) -- MADRID -- Including pembrolizumab (Keytruda) in the first-line treatment of metastatic HER2-positive gastric or gastroesophageal cancer improved progression-free survival (PFS), but potential harm was seen in PD-L1-negative... succesfully run! 0 Anläufe!